We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Oncimmune and Verily Pair Up to Conduct Autoantibody Profiling on Long COVID-19 Patients
Oncimmune and Verily Pair Up to Conduct Autoantibody Profiling on Long COVID-19 Patients
Immunodiagnostics developer Oncimmune has inked a contract with Alphabet subsidiary Verily Life Sciences to conduct autoantibody profiling on patients who have developed long COVID-19, defined as a symptomatic case of COVID-19 that lasts for more than four weeks.